Cargando…
The clinical prognostic significance of ezrin in patients with bone and soft tissue sarcomas: a meta‐analysis
Ezrin is a member of the ezrin–radixin–moesin (ERM) protein family and has been shown to be associated with poor prognosis in patients with a variety of solid tumors. However, the clinical prognostic significance of ezrin in patients with bone and soft tissue sarcomas remains unclear. Here, we perfo...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6768105/ https://www.ncbi.nlm.nih.gov/pubmed/31376222 http://dx.doi.org/10.1002/2211-5463.12713 |
_version_ | 1783455053760167936 |
---|---|
author | Wang, Feng Yu, Tao Ma, Chengbin Zhang, Haifei Zhang, Zhiyu |
author_facet | Wang, Feng Yu, Tao Ma, Chengbin Zhang, Haifei Zhang, Zhiyu |
author_sort | Wang, Feng |
collection | PubMed |
description | Ezrin is a member of the ezrin–radixin–moesin (ERM) protein family and has been shown to be associated with poor prognosis in patients with a variety of solid tumors. However, the clinical prognostic significance of ezrin in patients with bone and soft tissue sarcomas remains unclear. Here, we performed a systematic meta‐analysis by searching PubMed, the Cochrane Library Database, EMBASE, the Web of Science, and the CBM, WanFang Med Online and CNKI databases. In total, 19 studies with a total of 1316 bone and soft tissue sarcoma patients were included. Pooled analyses showed that ezrin overexpression was correlated with a higher rate of tumor metastasis (OR 6.59, 95% CI: 2.84–15.33, P < 0.01, P (FDR) < 0.01) and recurrence (OR 3.18, 95% CI: 1.88–5.37, P < 0.01, P (FDR) < 0.01) and a more advanced tumor grade (OR 3.252, 95% CI: 1.371–7.715, P = 0.01, P (FDR) = 0.03). Moreover, elevated ezrin expression could predict poor OS (HR 3.02, 95% CI: 2.35–3.89, P < 0.01, P (FDR) < 0.01), MFS (HR 5.22, 95% CI: 2.08–13.08, P < 0.01, P (FDR) < 0.01), and EFS (HR 1.07, 95% CI: 1.03–1.11, P < 0.01, P (FDR) < 0.01). Subgroup analyses revealed the underlying sources of heterogeneity. Publication bias was observed in the analysis of metastasis. Sensitivity analysis revealed that the results were robust. Our findings indicated that ezrin overexpression was significantly correlated with poor survival and more advanced tumor progression in bone and soft tissue sarcomas, which suggests that ezrin might be a valuable prognostic biomarker and a potential therapeutic target. |
format | Online Article Text |
id | pubmed-6768105 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-67681052019-10-01 The clinical prognostic significance of ezrin in patients with bone and soft tissue sarcomas: a meta‐analysis Wang, Feng Yu, Tao Ma, Chengbin Zhang, Haifei Zhang, Zhiyu FEBS Open Bio Research Articles Ezrin is a member of the ezrin–radixin–moesin (ERM) protein family and has been shown to be associated with poor prognosis in patients with a variety of solid tumors. However, the clinical prognostic significance of ezrin in patients with bone and soft tissue sarcomas remains unclear. Here, we performed a systematic meta‐analysis by searching PubMed, the Cochrane Library Database, EMBASE, the Web of Science, and the CBM, WanFang Med Online and CNKI databases. In total, 19 studies with a total of 1316 bone and soft tissue sarcoma patients were included. Pooled analyses showed that ezrin overexpression was correlated with a higher rate of tumor metastasis (OR 6.59, 95% CI: 2.84–15.33, P < 0.01, P (FDR) < 0.01) and recurrence (OR 3.18, 95% CI: 1.88–5.37, P < 0.01, P (FDR) < 0.01) and a more advanced tumor grade (OR 3.252, 95% CI: 1.371–7.715, P = 0.01, P (FDR) = 0.03). Moreover, elevated ezrin expression could predict poor OS (HR 3.02, 95% CI: 2.35–3.89, P < 0.01, P (FDR) < 0.01), MFS (HR 5.22, 95% CI: 2.08–13.08, P < 0.01, P (FDR) < 0.01), and EFS (HR 1.07, 95% CI: 1.03–1.11, P < 0.01, P (FDR) < 0.01). Subgroup analyses revealed the underlying sources of heterogeneity. Publication bias was observed in the analysis of metastasis. Sensitivity analysis revealed that the results were robust. Our findings indicated that ezrin overexpression was significantly correlated with poor survival and more advanced tumor progression in bone and soft tissue sarcomas, which suggests that ezrin might be a valuable prognostic biomarker and a potential therapeutic target. John Wiley and Sons Inc. 2019-09-03 /pmc/articles/PMC6768105/ /pubmed/31376222 http://dx.doi.org/10.1002/2211-5463.12713 Text en © 2019 The Authors. Published by FEBS Press and John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Articles Wang, Feng Yu, Tao Ma, Chengbin Zhang, Haifei Zhang, Zhiyu The clinical prognostic significance of ezrin in patients with bone and soft tissue sarcomas: a meta‐analysis |
title | The clinical prognostic significance of ezrin in patients with bone and soft tissue sarcomas: a meta‐analysis |
title_full | The clinical prognostic significance of ezrin in patients with bone and soft tissue sarcomas: a meta‐analysis |
title_fullStr | The clinical prognostic significance of ezrin in patients with bone and soft tissue sarcomas: a meta‐analysis |
title_full_unstemmed | The clinical prognostic significance of ezrin in patients with bone and soft tissue sarcomas: a meta‐analysis |
title_short | The clinical prognostic significance of ezrin in patients with bone and soft tissue sarcomas: a meta‐analysis |
title_sort | clinical prognostic significance of ezrin in patients with bone and soft tissue sarcomas: a meta‐analysis |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6768105/ https://www.ncbi.nlm.nih.gov/pubmed/31376222 http://dx.doi.org/10.1002/2211-5463.12713 |
work_keys_str_mv | AT wangfeng theclinicalprognosticsignificanceofezrininpatientswithboneandsofttissuesarcomasametaanalysis AT yutao theclinicalprognosticsignificanceofezrininpatientswithboneandsofttissuesarcomasametaanalysis AT machengbin theclinicalprognosticsignificanceofezrininpatientswithboneandsofttissuesarcomasametaanalysis AT zhanghaifei theclinicalprognosticsignificanceofezrininpatientswithboneandsofttissuesarcomasametaanalysis AT zhangzhiyu theclinicalprognosticsignificanceofezrininpatientswithboneandsofttissuesarcomasametaanalysis AT wangfeng clinicalprognosticsignificanceofezrininpatientswithboneandsofttissuesarcomasametaanalysis AT yutao clinicalprognosticsignificanceofezrininpatientswithboneandsofttissuesarcomasametaanalysis AT machengbin clinicalprognosticsignificanceofezrininpatientswithboneandsofttissuesarcomasametaanalysis AT zhanghaifei clinicalprognosticsignificanceofezrininpatientswithboneandsofttissuesarcomasametaanalysis AT zhangzhiyu clinicalprognosticsignificanceofezrininpatientswithboneandsofttissuesarcomasametaanalysis |